Currently, we only have preliminary data available for this agent in patients with heavily pretreated HER3 expressing metastatic breast cancer, demonstrating an ORR of 30
Currently, we only have preliminary data available for this agent in patients with heavily pretreated HER3 expressing metastatic breast cancer, demonstrating an ORR of 30.1% in...